BioDrugs

, Volume 14, Issue 2, pp 93–98 | Cite as

Juvenile Idiopathic Arthritis

Will Etanercept be an Improvement over Current Therapies?
Current Opinion
  • 34 Downloads

Abstract

Overexpression of cytokines in inflamed joints plays an important role in joint inflammation and in damage to articular tissue. Biological agents aimed at specifically antagonising tumour necrosis factor (TNF) are effective in the treatment of adult rheumatoid arthritis. A recent trial of etanercept, a genetically engineered fusion protein consisting of the Fc domain of human IgGl and the TNF receptor p75, has demonstrated that this agent is also well tolerated and effective in patients with juvenile idiopathic arthritis (JIA). Etanercept offers a promising new alternative for patients with JIA who have persistently active arthritis despite treatment with methotrexate. Further studies are needed to clarify whether etanercept is equally effective in the various onset types of JIA (oligoarthritis, polyarthritis and systemic arthritis), whether it can modify disease progression and whether it can be administered safely for long periods of time to children.

References

  1. 1.
    Cassidy JT, Nelson AM. The frequency of juvenile arthritis. J Rheumatol 1988; 15: 535–6PubMedGoogle Scholar
  2. 2.
    Towner SR, Michet Jr CJ, O’Fallon WM, et al. The epidemiology of juvenile arthritis in Rochester, Minnesota. Arthritis Rheum 1983; 26: 1208–13PubMedCrossRefGoogle Scholar
  3. 3.
    Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. JRheumatol 1998; 25: 1991–4Google Scholar
  4. 4.
    Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol 1992; 19 (33): 6–10Google Scholar
  5. 5.
    Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol. In pressGoogle Scholar
  6. 6.
    Harel L, Wagner-Weiner L, Poznanski AK, et al. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum 1993; 36: 1370–4PubMedCrossRefGoogle Scholar
  7. 7.
    Ravelli A, Viola S, Ramenghi B, et al. Radiologic progression in juvenile chronic arthritis patients treated with methotrexate. J Pediatr 1998; 133: 262–5PubMedCrossRefGoogle Scholar
  8. 8.
    Reiff A, Shaham B, Wood BP, et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 113–8PubMedGoogle Scholar
  9. 9.
    Wallace CA, Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 1604–7PubMedGoogle Scholar
  10. 10.
    Wallace CA. On beyond methotrexate treatment of severe juvenile rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: 499–504PubMedGoogle Scholar
  11. 11.
    Shaikov AV, Maximov AA, Spearansky AL, et al. Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis: preliminary results of a long-term study. J Rheumatol 1992; 19: 612–6PubMedGoogle Scholar
  12. 12.
    Wallace CA, Sherry DD. Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 1852–5PubMedCrossRefGoogle Scholar
  13. 13.
    Wulffraat N, van Royen A, Bierings M, et al. Autologous hematopoietic stem cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 1999; 353: 550–3PubMedCrossRefGoogle Scholar
  14. 14.
    Glass DN, Giannini EH. Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis Rheum 1999; 42: 2261–8PubMedCrossRefGoogle Scholar
  15. 15.
    De Benedetti F, Ravelli A, Martini A. Cytokines in juvenile rheumatoid arthritis. Curr Opin Rheumatol 1997; 9: 428–33PubMedCrossRefGoogle Scholar
  16. 16.
    Alonzi T, Fattori E, Lazzaro D, et al. Interleukin-6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187: 461–8PubMedCrossRefGoogle Scholar
  17. 17.
    Joosten LAB, Helsen MMA, van de Loo FAJ, et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/I mice. A comparative study using anti-TNF-α, anti-IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797–809PubMedCrossRefGoogle Scholar
  18. 18.
    Grom AA, Murray KJ, Luyrink L, et al. Patterns of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996; 39: 1703–10PubMedCrossRefGoogle Scholar
  19. 19.
    De Benedetti F, Pignatti P, Gerloni V, et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997; 24: 1403–9PubMedGoogle Scholar
  20. 20.
    Eberhard BA, Laxer RM, Andersson U, et al. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 1994; 96: 260–6PubMedCrossRefGoogle Scholar
  21. 21.
    De Benedetti F, Pignatti P, Massa M, et al. Soluble TNF receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Br J Rheumatol 1997; 36: 581–8PubMedCrossRefGoogle Scholar
  22. 22.
    De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin 6 levels with joint involvement and thrombo-cytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991; 34: 1158–63PubMedCrossRefGoogle Scholar
  23. 23.
    De Benedetti F, Massa M, Pignatti P, et al. Serum soluble IL-6 receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994; 93: 2114–9PubMedCrossRefGoogle Scholar
  24. 24.
    Cazzola M, Ponchio L, De Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythro-poietin production in the anemia associated with systemic-onset juvenile rheumatoid arthritis. Blood 1996; 87: 4824–30PubMedGoogle Scholar
  25. 25.
    De Benedetti F, Alonzi T, Moretta A, et al. IL-6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643–50PubMedCrossRefGoogle Scholar
  26. 26.
    De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an IL-6-mediated disease? J Rheumatol 1998; 25: 203–7PubMedGoogle Scholar
  27. 27.
    Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141–7PubMedCrossRefGoogle Scholar
  28. 28.
    Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9PubMedCrossRefGoogle Scholar
  29. 29.
    Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 763–9PubMedCrossRefGoogle Scholar
  30. 30.
    Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202–9PubMedGoogle Scholar
  31. 31.
    Finck B, Martin R, Fleishmann R, et al. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis (Enbrel ERA trial). Arthritis Rheum 1999;42 Suppl. : S117Google Scholar
  32. 32.
    Elliott MJ, Woo P, Charles P, et al. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumor necrosis factor-α (cA2). Br J Rheumatol 1997; 36: 589–93PubMedCrossRefGoogle Scholar
  33. 33.
    Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6 dependent tumor cell growth. Cancer Res 1993; 53: 851–6PubMedGoogle Scholar
  34. 34.
    Savino R, Ciapponi L, Lahm A, et al. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J 1994; 13: 5863–70PubMedGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Dipartimento di Scienze Pediatriche, IRCCS Polidinico San MatteoUniversità degli Studi di PaviaPaviaItaly

Personalised recommendations